Worldwide network for blood and marrow transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations by Aljurf, M et al.
eCommons@AKU 
Section of Haematology/Oncology Department of Medicine 
3-2020 
Worldwide network for blood and marrow transplantation (WBMT) 
recommendations for establishing a hematopoietic stem cell 
transplantation program in countries with limited resources (Part 
II): Clinical, technical and socio-economic considerations 
M Aljurf 
King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia 
D Weisdorf 
University of Minnesota, Minneapolis, MN, USA. 
S K. Hashmi 
King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia 
A Nassar 
National Cancer Institute, Cairo University, Cairo, Egypt 
E Gluckman 
Eurocord Hôpital Saint-Louis and University Paris Diderot, France 
See next page for additional authors Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_med_haematol_oncol 
 Part of the Hematology Commons, Oncology Commons, and the Pathology Commons 
Recommended Citation 
Aljurf, M., Weisdorf, D., Hashmi, S. K., Nassar, A., Gluckman, E., Mohty, M., Rizzo, D., Pasquini, M., 
Hamadani, M., Adil, S. (2020). Worldwide network for blood and marrow transplantation (WBMT) 
recommendations for establishing a hematopoietic stem cell transplantation program in countries with 
limited resources (Part II): Clinical, technical and socio-economic considerations. Hematology/Oncology 
and Stem Cell Therapy, 13(1), 7-16. 
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_med_haematol_oncol/61 
Authors 
M Aljurf, D Weisdorf, S K. Hashmi, A Nassar, E Gluckman, M Mohty, D Rizzo, M Pasquini, M Hamadani, and 
Salman Adil 
This article is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_med_haematol_oncol/61 
Worldwide Network for Blood and Marrow
Transplantation (WBMT) recommendations
for establishing a hematopoietic stem cell
transplantation program in countries with
limited resources (Part II): Clinical, technical
and socio-economic considerationsq
M. Aljurf a,*, D. Weisdorf b, S.K. Hashmi a,c, A. Nassar d, E. Gluckman e,
M. Mohty f, D. Rizzo g, M. Pasquini g, M. Hamadani g, W. Saber g, P. Hari g,
M. Kharfan-Dabaja h, N. Majhail i, U. Gerges j, A. Ali Hamidieh k,
F. Hussain a, A. Elhaddad d, H.K. Mahmoud d, A. Tbakhi l, T.B. Othmanm,
R.M. Hamladji n, M.A. Bekadja o, P. Ahmed p, A. Bazarbachi q, S. Adil r,
S. Alkindi s, S. Ladebm, D. Dennison s, M. Patel t, P. Lu u, A.E. Quessar v,
S. Okamotow, Y. Atsuta x, A. Alhejazi y, M. Ayas a, S.O. Ahmed a,
N. Novitzky z, A. Srivastava aa, A. Seber ab, H. Elsolh a, A. Ghavamzadeh k,
D. Confer g, Y. Kodera ac, H. Greinix ad, J. Szer ae, M. Horowitz g,
D. Niederwieser ac,af
aHematology Department, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
bUniversity of Minnesota, Minneapolis, MN, USA
cDepartment of Medicine, Mayo Clinic, Rochester, MN, USA
dNational Cancer Institute, Cairo University, Cairo, Egypt
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Abstract
The development of hematopoietic stem cell transplantation (HSCT) programs can face signif-
icant challenges in most developing countries because such endeavors must compete with other
government health care priorities, including the delivery of basic services. While this is may be
a limiting factor, these countries should prioritize development of the needed expertise to
offer state of the art treatments including transplantation, by providing financial, technologi-
cal, legal, ethical and other needed support. This would prove beneficial in providing successful
programs customized to the needs of their population, and potentially provide long-term cost-
savings by circumventing the need for their citizens to seek care abroad. Costs of establishing
HSCT program and the costs of the HSCT procedure itself can be substantial barriers in devel-
oping countries. Additionally, socioeconomic factors intrinsic to specific countries can influ-
ence access to HSCT, patient eligibility for HSCT and timely utilization of HSCT center
capabilities. This report describes recommendations from the Worldwide Network for Blood
and Marrow Transplantation (WBMT) for establishing HSCT programs with a specific focus on
developing countries, and identifies challenges and opportunities for providing this specialized
procedure in the resource constrained setting.
 2020 The Authors. Published by Elsevier Ltd. on behalf of King Faisal Specialist Hospital &
Research Centre and Elsevier Inc. on behalf of The American Society for Transplantation and
Cellular Therapy. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The establishment of hematopoietic stem cell transplanta-
tion (HSCT) programs in developing countries can enhance
and improve tertiary care health services. There are various
positive attributes that favor the establishment of such a
high-profile venture; however, there are also significant
obstacles to be addressed.
Since the obvious issue in most economies is cost distri-
bution and budget allocation for the populations’ health-
care, public health measures take precedence over the
non-communicable chronic diseases. However, over time,
there has been increasing focus on chronic diseases particu-
larly cancers as these have become leading cause of mortal-
ity in both developing and developed nations. Thus there
has been an exponential growth of both prevalence and inci-
* Corresponding author at: Oncology Center, King Faisal Specialist
Hospital & Research Center, Riyadh, Saudi Arabia.
E-mail address: maljurf@kfshrc.edu.sa (M. Aljurf).
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dence of the diseases which can be cured by HSCT including
sickle cell anemia, thalassemia, leukemia, myeloma, lym-
phoma, immunodeficiencies and metabolic disorders. As a
result, many new HSCT centers have been opening in the
developing nations.
In most developing countries, a HSCT program has to
compete for allocation of limited funds with other priorities
for basic health care services such as food, sanitation,
immunization, population control and prevention of com-
municable diseases. Developing countries should also have
the expertise to offer ‘state-of-the art’ treatments, includ-
ing HSCT which can provide treatment locally at a much
lower cost than abroad.
The most important step would be to provide financial,
technological, legal, ethical and other support for local indi-
viduals and institutions to proactively establish new HSCT
program. The goal is to develop a customized local experi-
ence tailored to each developing country and also to allow
local dissemination of this experience as it evolves [1].
While establishing a HSCT program in a developing coun-
try, one should take into consideration several difficulties.
Financial, technologic, logistic, social, and the availability
of skilled manpower are all potential difficulties. Given
the exponential growth in both the numbers of HSCT world-
wide and the establishment of new HSCT centers in the high
and low income countries, the Worldwide Network for Blood
and Marrow Transplantation (WBMT) has recognized the
need to provide guidance to institutions and individuals
who are considering start of a new HSCT center. Part I of
this report describes the absolute minimum, minimum, pre-
ferred, and ideal requirements for the establishment of a
new HSCT program. This part II of the series describes the
clinical, technical and financial considerations for establish-
ing a HSCT program in the resource constrained setting (typ-
ical for developing countries).
Financial issues and cost of establishing a
transplantation program
HSCT remains a highly specialized, complex, resource
intense and costly medical procedure. A 2009 report from
the Agency for Healthcare Research and Quality (AHRQ) in
the United States (US) showed that HSCT was among the
top ten procedures with the greatest increase in hospital
costs from 2004 to 2007. Total US national costs of HSCT
hospitalization increased from $694 million to $1.3 billion
over this time period [2].
Thus establishment of a dedicated center for this costly
procedure requires a comprehensive understanding of eco-
nomic indicators and challenges. There are four main eco-
nomic evaluations that provide information to guide
decision making on the basis of the value for money: cost
minimization, cost benefit, cost effectiveness, and cost
utility.
Cost minimization is commonly practiced in HSCT when-
ever lower cost, equally effective treatment is chosen over
more expensive treatments. Cost benefit analysis is rarely
used in procedures like transplant because it requires
assignment of monetary costs to measure clinical benefits
which are difficult to assign in this complex setting with
potential for long-term cure for a proportion of recipients.
Cost utility analysis is a specific type of cost effective-
ness analysis where outcomes are adjusted to consider
health related quality of life, so that a cure without treat-
ment sequelae is considered more valuable than a cure
resulting continuing health disabilities [3].
In this paper we will emphasize HSCT interventions that
focus primarily on cost-effectiveness or cost-utility. To
develop a cost containment program, proof of both clinical
and economic effectiveness is preferred before widespread
adoption of new technologies [4].
It is critical to identify the exact drivers of cost before
considering initiation of a HSCT program. Little available
data to evaluate the exact drivers of HSCT costs in develop-
ing countries. A recent study of establishment of a cancer
center in a developing country (Rwanda) indicated that
$556,105 US dollars was the necessary start-up funding to
implement the cancer program [5]. The annual operating
cost of the cancer program was found to be $957,203 US$.
Radiotherapy, labor, and chemotherapy were the most sig-
nificant cost drivers, however radiotherapy required sending
patients out of country because there were no radiation
units in Rwanda. Labor accounted for 21%, whereas
chemotherapy, supportive medications, and consumables
accounted for 15% of the costs. While the radiation therapy
is not routinely performed for HSCT, it is necessary part of
certain preparative regimens and thus establishment of a
radiation therapy unit is likely to significantly increase the
costs.
The high costs of HSCT can be presumably attributed to
various factors as discussed below (Fig. 1).
Patient related factors
When designing a national program for HSCT in a developing
country, few patient related factors can be assessed for
cost reduction. Although there is no consistent correlation
between costs and patient age, sex, performance status,
or disease risk, in some more recent studies, advanced risk
disease was a significant predictor of higher costs [6–10].
In view of the limited resources in developing countries,
health authorities should allocate available resources to the
best priorities where low cost inputs yield high dividends.
However, there are no clear recommendations and each
country needs to adopt the policies that satisfy its popula-
tion needs.
Considering the young median age in many developing
countries, it would be prudent to initially make HSCT avail-
able to younger patients with curable diagnoses and longer
lifespan benefit. Subsequently, expanding eligibility for
HSCT to older and advanced disease subjects may be appro-
priate as the program’s experience develops.
Transplant center experience
Cost reduction and clinical outcomes have been shown to
improve with increasing institutional experience [11]. How-
ever, this economic advantage may be offset as the com-
plexity of treated patients increases and more aggressive
supportive interventions are applied, resulting in a plateau
in the improvement curve [11–13]. Growing local expertise
Worldwide Network for Blood and Marrow Transplantation (WBMT) 9
and adopting cost effective practices can limit total costs
and improve transplant outcomes.
Human resources and continuous training
Availability of well-trained staff at different steps of trans-
plantation with continuous training and to advance their
knowledge is a cornerstone of any successful transplant pro-
gram. Migration of health care professionals from develop-
ing to developed countries deprives the developing world
of valuable and essential human resources [14]. Countries
should strengthen health system requirements, including
physical infrastructure and skilled human resources to meet
the multidisciplinary requirements of HSCT aiming for high
quality and safety as fundamental principles. International
cooperation and twinning with other institutions in devel-
oped countries could facilitate exchange of expertise across
the globe. Adequate attention for neutropenic and hygienic
precautions and any other measures to reduce infection
should be considered.
Donor selection and HLA typing
With the advance in immunogenetics and transplantation
immunology, particularly in the structure and function of
the HLA system in the 1990s, new and efficient technologies
for HLA typing emerged and progressed [15,16].
According to the guidelines of World Marrow Donor Asso-
ciation (WMDA) and European Federation for Immunogenet-
ics (EFI), high-resolution HLA typing should be performed
both for HSCT recipients and donors. HLA typing should also
include the HLA-C locus due to the recognized role of this
locus in graft rejection [17,18].
The technology for HLA typing has evolved from the sero-
logical level to the cellular level, and recently to the molec-
ular level. Serotyping was the mainstream method for HLA
typing and played a critical role in organ transplantation
before the 1990s. However, most HLA antisera are poly-
clonal with lower specificity and variable sensitivity. There-
fore, molecular methods to type HLA at the DNA level have
replaced serologic and cellular typing.
Commonly used DNA based HLA typing methods include
PCR based sequence specific primers (PCR-SSP), and PCR
based restriction fragment length polymorphism (PCR-
RFLP), single-strand conformation polymorphism (PCR-
SSCP), sequence-specific oligonucleotide (PCR-SSO) and sin-
gle nucleotide polymorphism (PCR-SNP). PCR-SSP genotyp-
ing was a commonly used method for HLA typing in
clinical laboratories worldwide. PCR-SSP and PCR-SSO meth-
ods have a high cost and prolonged operation time, there-
fore are rarely used for HLA typing at present.
Fig. 1 Major determinants of costs in establishment of an HSCT program. HSCT: hematopoietic stem cell transplant; MRI: Magnetic
resonance imaging; PET: positron emission tomogram; HLA: human leukocyte antigen; IT: information technology; EMR: electronic
medical records; BM: bone marrow; PBSC: peripheral blood stem cells; PRBC: packed red blood cells; GVHD: graft-versus-host-
disease; UCB: umbilical cord blood; haplo: haploidentical; RD: related donor; URD: unrelated donor.
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PCR-SNP is a simple and fast method with high resolution
and will become more commonly used as the technology
continues to improve. At present, PCR-sequence-based typ-
ing (PCR-SBT) technology has significant advantages over
other HLA typing methods in terms of accuracy, efficiency
and automation. In addition, the operational costs have
been greatly reduced [15]. It is recommended that new pro-
grams in developing countries with limited resources should
start by performing matched sibling transplantation, where
high resolution typing may not be necessary and some risks
are reduced.
Outsourcing HLA typing can be a cost-effective alterna-
tive in developing countries where laboratories with
immunogenetic capabilities and expertise are not yet avail-
able. Many companies throughout the developed countries
offer molecular-based HLA typing at very competitive
prices, particularly for bulk contracts.
Conditioning intensity
Both the intensity and duration of conditioning affect the
cost of HSCT. Large studies confirmed that the costs associ-
ated with reduced intensity regimens are lower, with fewer
median hospital days within the first year of the transplant
compared with high-dose or myeloablative regimens [8].
Myeloablative allogeneic HSCT is not only associated with
a higher frequency and severity of short-term toxicities, but
also late complications such as a higher likelihood of infer-
tility, growth retardation in children and new primary malig-
nancies. This may also increase on the use of blood
products, risk of infections, transplant-related mortality,
and length of hospital stay. Despite these advantages,
lower-intensity regimens must be adapted for important
patient and disease related variables as a recent multicen-
ter trial showed a clear advantage in reducing relapse of
AML using myeloablative regimens in younger fit patients
[19].
Several recent studies had suggested that intermediate
intensity regimens with a 20–30% reduction in dose inten-
sity could reduce toxicity without causing significant
increases in the risk of relapse or overall worse transplanta-
tion outcomes [20–22].
The cost and limited availability of radiation therapy in
many developing countries should not be a major obstacle
as non-radiation based conditioning regimens are available
for nearly all diseases or conditions in which HSCT is
indicated.
Blood product support
In adult recipients of autologous HSCT, two randomized tri-
als have demonstrated similar rates of bleeding when ther-
apeutic rather than prophylactic strategy for platelet
transfusion was used [23,24]. Both American Society of Clin-
ical Oncology and British Society of Haematology recom-
mend that therapeutic platelet transfusion strategy could
be used in autologous HSCT setting which will result in less
platelet usage and substantial cost savings [25,26]. In allo-
genic HSCT, a randomized study subgroup analysis found
similar rates of bleeding when low dose of platelet
(1.1  1011) was used compared to medium (2.2  1011) or
high dose (4.4  1011). This led to a decreased number of
platelets transfused per patient at doses between
1.1  1011 and 4.4  1011 platelets per m2 with similar
bleeding events [27]. Irradiated blood products should be
utilized according to international guidelines.
Performing autologous stem cell transplant without
stem cell cryopreservation
Cryopreservation of stem cells needs a relatively advanced
stem cell processing laboratory with mechanical, controlled
rate freezers. Several reports have described the feasibility
of non-cryopreserved G-CSF mobilized whole blood or autol-
ogous bone marrow (with or without prior administration of
G-CSF). Stem cell graft containing blood units or bone mar-
row can be briefly stored in a standard blood bank refriger-
ator at +4 C until infusion [28–30].
The outcomes of autologous HSCT for multiple myeloma
using non-cryopreserved stem cells and without G-CSF sup-
port has recently been described by several centers [31–
34]. This technique depends on abbreviated conditioning,
with one day of high dose melphalan for myeloma or short
duration conditioning for lymphoma patients. This tech-
nique avoids the need for costly cryopreservation technol-
ogy and also avoids the possible side effects described
with infusion of dimethyl sulfoxide (DMSO) which is required
for cryopreservation. These autologous transplantation
techniques were reported to yield early engraftment and
reduced hospital stay with significant cost savings. Out-
comes were comparable to conventional conditioning with
cryopreserved stem cells in multiple myeloma patients
[31–34]. Two recent studies of non-cryopreserved auto-
grafts from developing countries utilizing post-HSCT G-CSF
also indicate comparable engraftment rates to cryopre-
served autografts [35,36].
Thus, for a new HSCT center, it may not be necessary to
have mechanical freezers in place for autograft cryopreser-
vation, as safety and efficacy of utilizing non-cryopreserved
stem cells is evident.
Graft source
Peripheral blood stem cells (PBSC) are known to offer more
rapid neutrophil and platelet recovery compared to bone
marrow grafts with an early cost reduction of approximately
30% compared to bone marrow in some studies [37–39]. The
use of PBSC can lead to specific resource saving in hospital-
ization, platelet transfusions and use of growth factors
[40,41].
Unlike autologous transplantation, chronic GVHD is a
serious late complication of allogeneic HSCT and results in
serious morbidity and mortality. Most studies report a
higher incidence of chronic GVHD with the use of allogeneic
PBSCs, which may potentially offset the early cost savings.
Appropriate selection of cases and developing well-
informed indications for the use of PBSCs could reflect
favorably on procedural costs and transplant outcomes [42].
In a recent study by the Center for International Blood
and Marrow Transplant Research (CIBMTR), the use of PBSCs
resulted in an acceptable alternative for transplanting
patients with aplastic anemia in developing countries, as
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PBSC grafts were associated with faster engraftment, lower
frequency of infections, and a lower likelihood of graft
rejection in heavily pretransfused patients [43].
However, in autologous HSCT there is strong evidence of
clinical benefit and cost savings using PBSCs which has been
consistently reported [44–47].
Alternative donors and graft manipulation:
The use of alternative donors, specifically HLA-compatible
unrelated donors (URD), has emerged as a significant driver
of costs, even beyond the costs of stem cell procurement
[8,48,49]. Among the various sources of alternative donors,
myeloablative umbilical cord blood (UCB) transplantation is
associated with the highest costs, followed by matched
URD. Accordingly, these donor sources should not be consid-
ered a priority in developing countries for a new HSCT
program.
The preferred and most cost effective alternate donor
transplantation modality in developing countries may be a
related (family-member) haploidentical transplantation
using post-transplant cyclophosphamide (PTCy) for GVHD
prevention. The posttransplant course, however, might
require more experience as conventional, URD HSCT.
Alternatives to PTCy for haploidentical transplantation
use different methods of T-cell depletion (TCD) of the donor
graft or other cellular manipulation which are complex and
require advanced and costly stem cell processing technology
[50].
Cost of supportive care medications:
Pharmacy costs range from 8% to 39% of the total expendi-
tures in HSCT. Hematopoietic growth factors, GVHD prophy-
lactic drugs and antimicrobials are the major contributors to
pharmacy costs [51–53]. Several generic forms are now
available for fluconazole and more recently for voriconazole
as well [54]. This could help offset some costs, provided
that these alternative products demonstrate similar effi-
cacy. Pharmacy costs are expected to continuously rise
given the changes in HSCT practice with increasing use of
newer immunosuppressive regimens and the higher cost of
new anti-infective agents [52]. The long-term excess phar-
macy costs for patients with chronic GVHD who may require
prolonged immunosuppressive treatments are unpredictable
and may be large [52].
A biosimilar drug is a similar copy of an approved inject-
able original biologic substance, which may be available
after the original patent protection has expired [55]. Since
drugs are produced by cultured cells, small biological differ-
ences between original and biosimilars may exist. However,
the use of well-established biosimilars should be considered
for cost containment and for improved availability of drugs
needed for HSCT provided that they are demonstrably as
safe and efficacious as the originator product. If properly
evaluated and clinical effectiveness is proven these biosim-
ilars, their generally reduced costs may contribute to the
long-term financial sustainability of HSCT programs
[55–57]. Several biosimilars of G-CSF are less expensive
alternatives to the original brand product. The European
Medicines Agency (EMA) has recently approved several
biosimilar versions after the patent of the original G-CSF
brand expired in Europe in 2006 [55].
Several G-CSF biosimilars have been evaluated in the set-
ting of stem cell mobilization for autologous HSCT. Results
show similar mobilization yields with comparable safety
profiles as the originator G-CSF. Moreover, both myeloid
and platelet recovery times are similar to the originator
G-CSF product [56–62]. This non-inferiority model could
be extrapolated to other medications, ultimately leading
to significant cost saving. Highly reputable pharmaceutical
companies are already involved in the manufacturing pro-
cess of several biosimilar medications essential for HSCT
[63]. Table 1 presents several currently approved biosimi-
lars which are used in the HSCT arena. The utilization of
these biosimilars should be explored in developing countries
when local approvals are in place.
However, the major problems encountered beyond the
costs of certain drugs are reliable availability. The experi-
ence in different countries and continents underlines the
need to check the availability and approval of the essential
drugs to perform HSCT. In some countries cyclosporine is
only available orally but not intravenously, Busulfan may
not be available at all and the import of the drug is some-
times very difficult. The WBMT prepared a list for essential
drugs, which should be available or for a successful pro-
gram. Licensing of drugs in a country may depend on the
demand and some drugs needed for HSCT may be used only
for HSCT. Sometimes availability of drug needed for HSCT
will also improve the treatment of the underling disease
before HSCT. Close interaction with the health authorities
of the country is recommended to guide informed policies
for specific drug availabilities.
Post transplantation factors
Several post-transplant factors may greatly increase costs.
Prolonged hospitalization and late complications are the
most significant drivers of costs. Designing programs for
post-transplant care including home health services and
outpatient follow up systems allowing safe follow up at
either their own homes or at a hostel where a well-trained
and qualified nurse can monitor patients who need less
aggressive intervention, have been found to reduce post-
transplant costs [64].
Socioeconomic and other factors
In many developing countries, many acute leukemia
patients die before referral to a national or regional HSCT
center. This indirectly leads to a relatively larger proportion
of HSCT being done for non-neoplastic indications such as
bone marrow failure and hemoglobinopathies, diseases
more permissive of delays until HSCT. The time from diag-
nosis to HSCT is likely to be longer in developing countries
with the resulting unintended consequences of having sicker
candidates present for HSCT due to advanced disease, poor
performance status, more infections or transfusion alloim-
munization. The consequences of delay may be higher costs
of HSCT and poorer outcomes. Efforts to shorten the time
from diagnosis to HSCT should be considered a priority in
developing countries. Increasing public awareness and
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patient education about essential hygienic and infection
control measures as well as utilization of social services
may also help educate patients and caregivers about recom-
mendations that will increase HSCT success in developing
countries.
The Human Development Index (HDI) is used by the Uni-
ted Nations Organization to evaluate a country’s socioeco-
nomic achievements based on three parameters:
longevity, knowledge, and standard of living [65]. The num-
ber of transplants performed per unit population, as well as
early and long-term outcomes are directly related to the
HDI [66–70].
Information technology (IT) and quality
benchmarks:
The most effective way to improve HSCT outcomes is to
establish and maintain good quality programs in transplant
centers. Established databases to define benchmarks for
error reduction and improvement of outcomes. It is desir-
able for each HSCT center to have an internal database with
experienced data managers and staff who can maintain the
database and report the data to global registries (e.g. EBMT,
CIBMTR or others). Developments in artificial intelligence
(AI) for some aspects of tertiary care centers’ management
is predicted to lower costs. These may include machine
learning algorithms in medical billing, supply chain manage-
ment, scheduling efficiencies, virtual radiology (for image
interpretation), and prevention of re-admissions [71–77].
Since many AI companies are currently originating in
developing countries, it may be valuable to explore the
application of AI systems at HSCT startup with the goal of
cost-reduction.
Telemedicine in developing countries
Available techniques today allow intensive cooperation with
experienced centers. Pilot programs are currently active
across the world. This technique is particularly valuable
where a very experienced HSCT program director is not
available. Important guidelines for success involve training
of the local senior physicians, suitable facilities and labora-
tory capabilities in place and regular communication with
outside consultants.
Conclusions
Establishment of a HSCT center in countries with limited
resources is a multistep endeavor requiring many financial,
social, technical and human resources and involvement of
physicians, health authorities, politicians, nurses and scien-
tific societies. The main obstacle in some countries remains
constrained resources and inexperience which may lead to
high operating and maintenance costs, but may also compli-
cate initial organization of a program. The WBMT has out-
lined the major drivers of costs for a HSCT program and
presents general recommendations to help limit initial pro-
gram costs. New cost-effectiveness studies from developing
countries for each aspect of HSCT (conditioning type, GVHD
management, IT systems implementation, graft source and
donor choice, laboratory testing, drug costs [and biosimilar
use], blood bank utilization [defined thresholds for PRBC
Table 1 List of some Biosimilars approved in the United States and the European Union pertaining to HSCT*.
Generic/molecule Biosimilar Year approved Use in HSCT
Filgrastim Tevagrastim 2008 (EMA) Mobilization of peripheral stem
cells for autologous HSCTRatiograstim 2008 (EMA)
Filgrastim Hexal 2009 (EMA)
Zarzio 2009 (EMA)
Accofil 2014 (EMA)
Zarxio 2015 (US-FDA)
Rituximab Truxima 2017 (EMA) Treatment of chronic GVHD
Rixathon 2017 (EMA)
Ritemvia 2017 (EMA)
Infliximab Inflectra 2013 (EMA); 2016 (US-FDA) Treatment of acute GVHD
Flixabi 2016 (EMA)
Etanercept Benepali 2016 (EMA) Treatment of acute GVHD
Erelzi 2016 (US-FDA); 2017 (EMA) Treatment of BOS
Treatment of IPS
Enoxaparin Inhixa 2016 (EMA) DVT prophylaxis
Thorinane 2016 (EMA) DVT treatment
EMA: European Medicines Agency; US-FDA: United States Food and Drug Administration; GVHD: Graft-versus-host-disease; BOS: Bron-
chiolitis obliterans syndrome; IPS: Idiopathic pulmonary syndrome; DVT: Deep venous thrombosis; HSCT: Hematopoietic stem cell
transplantation.
*The table list only some of the approved biosimilars and not intended to be inclusive of all approved biosimilars. WBMT is working on a
separate publication that will have a complete list of approved biosimilars.
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and platelet transfusion] may be of particular value in
improving the safety and affordability of HSCT.
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